CA-HILLSTONE-NETWORKS
Hillstone Networks, a leading provider of innovative and accessible cybersecurity solutions, has announced a major upgrade to its operating system, Hillstone StoneOS 5.5R10. The latest upgrade delivers AI-based high performance threat protection, centralized Zero Trust control and management, and further simplification of security operations and system optimization, among over 300 new features. The new functionality enhances the security posture of customer environments and further streamlines security operations with an easy upgrade path.
Threat protection enhancements with AI technology
The new StoneOS leverages AI technology to provide ML-based threat detection for encrypted traffic without the need for decryption. It also features intelligent DDoS protection and DGA detection. In addition, included is a blacklist extension that empowers the Perimeter Traffic Filtering (PTF) function and delivers more protection against threats.
Centralized Zero Trust control and management
Advanced ZTNA implements centralized management for ZTNA policies through Hillstone Security Management (HSM), and supports intelligent connection to ZTNA gateways, single packet authentication (SPA), multiple vendor Operating System support for ZTNA clients, along with a ZTNA portal. The new features provide a better user experience with improved overall operations and management of the ZTNA solution.
Smarter interconnectivity with extended VPN capabilities
The extended VPN features support ECMP and failover for intelligent VPN routing and provide IPSec VPN tunnel establishment options by configuring custom ports and auto-negotiation. These features bring better bandwidth utilization and improve connectivity, ensuring the business remains undisrupted.
Streamlined system operations offload redundant workloads
The latest StoneOS introduces a simplified start-up wizard and automated NAT redundancy check to facilitate system operations, improving overall productivity for organizations by streamlining the workload of system administrators.
Robust system-wide enhancements further ensure business continuity
System availability is improved across the board in the latest release, with support for advanced High Availability (HA) and the graceful restart of Border Gateway Protocol (BGP), further ensuring that business services remain uninterrupted for organizations.
“The transition from the traditional, edge-based security model to the distributed workforce model is a seismic change, triggered primarily by the pandemic-induced work from home mandate, but the impact will evolve gradually, and therefore the solutions we deliver need to address the associated challenges,” states Tim Liu, CTO and co-founder, Hillstone Networks, “The latest iteration of StoneOS continues to address the challenges faced by SecOps teams, and the constant risks faced by enterprises globally. Enhanced AI-driven threat protection, better integration, centralized control and management, and streamlined operations are all critical in delivering a stable and strategic approach to cyber-resilient cybersecurity environments.”
StoneOS is the foundation for all Hillstone next-generation firewalls, which has been recognized in the 2022 Gartner® Magic Quadrant™ for Network Firewalls for the 9th consecutive year as a Visionary. StoneOS 5.5R10 is now generally available.
About Hillstone Networks
Hillstone Networks’ innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyber threats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom